Effects of SARS-CoV-2 vaccination on antibody production and immune function

doi:10.3969/j.issn.1673-8640.2022.08.005

Abstract

Abstract:

Objective To investigate the changes of antibody production and immune function in healthy subjects after receiving novel coronavirus-inactivated vaccine（Vero cell）. Methods Totally,121 volunteers were classified into two dose and three dose groups. Severe acute respiratory syndrome coronavirus 2（SARS-CoV-2） total antibodies（IgG+IgM+IgA）,SARS-CoV-2 IgG,SARS-CoV-2 receptor binding domain（RBD） specific neutralizing antibody,lymphocyte subsets and 12 cytokine levels were determined before the first dose,at 7 d after the second dose,before the third dose（half a year after the second dose） and at 7 d after the third dose. Results After the volunteers received the vaccine in the two dose group,the positive rates of SARS-CoV-2 total antibody and SARS-CoV-2 IgG were all 93.44%,and the positive rate of neutralizing antibody of SARS-CoV-2 was 81.96%. For the three dose group,the positive rate of SARS-CoV-2 total antibody was 100.00%,and the positive rate of SARS-CoV-2 IgG was 93.33%. The total antibody level of SARS-CoV-2 in the three dose group at 7 d after the third dose was higher than that in the two dose group at 7 d after the second dose（P<0.001）,and the neutralizing antibody level was also statistically significant（P<0.01）. The percentage of T follicular helper cell（Tfh） in the two dose group at 7 d after the second dose（11.40%） was higher than that before the first dose（3.92%）（P<0.01）. There was no statistical significance in lymphocyte subsets and 12 cytokine levels before the first dose and at 7 d after the second dose in the two dose group,and there was no statistical significance in the three dose group（P>0.05）. Conclusions Neutralizing and reactive antibodies can be produced after vaccination with novel coronavirus-inactivated vaccine（Vero cell）. Vaccination does not affect the immune function of the humans.

Key words: Severe acute respiratory syndrome coronavirus 2, Inactivated vaccine, Neutralizing antibody, Lymphocyte subset, Cytokine

CLC Number:

R446.1

TAN Meiyu, SHU Jie, XUAN Binbin, ZHOU Lida, LI Hong, HOU Shangwei, SHENG Huiming. Effects of SARS-CoV-2 vaccination on antibody production and immune function[J]. Laboratory Medicine, 2022, 37(8): 729-734.

Figures/Tables 7

References 14

[1]	World Health Organization. Director-general's remarks at the media briefing on 2019-nCoV on 11 February 2020[R]. 2020.
[2]	新冠病毒疫苗接种技术指南(第一版)[J]. 中国病毒病杂志, 2021, 11(3):161-162.
[3]	新型冠状病毒肺炎疫情防控期间开展肺功能检查的专家共识[J]. 中华结核和呼吸杂志, 2020, 68(4):302-307.
[4]	上海市2019冠状病毒病综合救治专家共识[J]. 中华传染病杂志, 2020, 38(3):134-138.
[5]	KLEIN S L, PEKOSZ A, PARK H S, et al. Sex,age,and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population[J]. J Clin Invest, 2020, 130(11):6141-6150. DOI URL
[6]	ZHOU P, YANG X L, WANG X G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798):270-273. DOI URL
[7]	KRAMMER F. SARS-CoV-2 vaccines in development[J]. Nature, 2020, 586:516-527. DOI URL
[8]	GAO Q, BAO L, MAO H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2[J]. Science, 2020, 369(6499):77-81. DOI URL
[9]	LAZARUS R, BAOS S, CAPPEL-PORTER H, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines(ChAdOx1 or BNT162b2) with seasonal IFNluenza vaccines in adults in the UK(ComFluCOV):a multicentre,randomised,controlled,phase 4 trial[J]. Lancet, 2021, 398(10318):2277-2287. DOI URL
[10]	XIA S, DUAN K, ZHANG Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes:interim analysis of 2 randomized clinical trials[J]. JAMA, 2020, 324(10):951-960. DOI URL
[11]	JUNO J A, TAN H X, LEE W S, et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19[J]. Nat Med, 2020, 26(9):1428-1434. DOI URL
[12]	严雨晨, 赵超, 牛辰, 等. 细胞因子风暴易发因素的检测和动态监测对重型和危重型新型冠状病毒肺炎的防控作用[J]. 中华传染病杂志, 2020, 38(3):189-192.
[13]	石亚玲, 区静怡, 陈星, 等. 多种炎症指标在新型冠状病毒肺炎的表达水平及临床应用价值[J]. 中华检验医学杂志, 2020, 43(4):346-351.
[14]	宣彬彬, 孙寒晓, 武娇祥, 等. 1例COVID-19患者的实验室指标变化及意义[J]. 国际检验医学杂志, 2021, 42(9):1149-1152.

时间点	CRP/ （mg/L）	白细胞计数/（×10⁹/L）	中性粒细胞比值/%	淋巴细胞比值/%	单核细胞比值/%
接种前	1.72±0.95	6.78±0.20	58.82±1.10	33.14±1.03	5.86±0.19
接种第2针后7 d	0.96±0.16	6.39±0.20	58.02±0.98	33.96±0.86	5.73±0.21
时间点	嗜酸性粒细胞比值/%	嗜碱性粒细胞比值/%	中性粒细胞绝对值/（×10⁹/L）	淋巴细胞绝对值/（×10⁹/L）	单核细胞绝对值/（×10⁹/L）
接种前	1.74±0.13	0.42±0.02	4.03±0.15	2.24±0.08	0.39±0.01
接种第2针后7 d	1.84±0.15	0.43±0.02	3.79±0.19	2.13±0.07	0.35±0.01
时间点	嗜酸性粒细胞绝对值/（×10⁹/L）	嗜碱性粒细胞绝对值/（×10⁹/L）	红细胞计数/（×10¹²/L）	血红蛋白/ （g/L）	血小板计数/（×10⁹/L）
接种前	0.12±0.01	0.02±0.00	4.67±0.07	138.32±2.19	270.88±8.06
接种第2针后7 d	0.11±0.01	0.02±0.00	4.66±0.07	133.86±2.41	256.50±9.05

时间点	CRP/ （mg/L）	白细胞计数/（×10⁹/L）	中性粒细胞比值/%	淋巴细胞比值/%	单核细胞比值/%
接种前	1.72±0.95	6.78±0.20	58.82±1.10	33.14±1.03	5.86±0.19
接种第2针后7 d	0.96±0.16	6.39±0.20	58.02±0.98	33.96±0.86	5.73±0.21
时间点	嗜酸性粒细胞比值/%	嗜碱性粒细胞比值/%	中性粒细胞绝对值/（×10⁹/L）	淋巴细胞绝对值/（×10⁹/L）	单核细胞绝对值/（×10⁹/L）
接种前	1.74±0.13	0.42±0.02	4.03±0.15	2.24±0.08	0.39±0.01
接种第2针后7 d	1.84±0.15	0.43±0.02	3.79±0.19	2.13±0.07	0.35±0.01
时间点	嗜酸性粒细胞绝对值/（×10⁹/L）	嗜碱性粒细胞绝对值/（×10⁹/L）	红细胞计数/（×10¹²/L）	血红蛋白/ （g/L）	血小板计数/（×10⁹/L）
接种前	0.12±0.01	0.02±0.00	4.67±0.07	138.32±2.19	270.88±8.06
接种第2针后7 d	0.11±0.01	0.02±0.00	4.66±0.07	133.86±2.41	256.50±9.05

[1]	YANG Xue, ZHU Jun, JIANG Lingli, WANG Qing, HU Xiaobo. Evaluation on the consistency of blind sample test results of 9 SARS-CoV-2 nucleic acid determination kits in Shanghai，China [J]. Laboratory Medicine, 2023, 38(8): 776-780.
[2]	LIU Yanan, XIA Min, HU Shaohua, ZHENG Yue, ZHANG Hong. Roles of lymphocyte subsets，inflammatory factors and NT-proBNP in diagnosis of Kawasaki disease [J]. Laboratory Medicine, 2023, 38(6): 532-537.
[3]	XIAO Xiumei, LIANG Chao, LIU Caihong, LI Xiaoguang. Comparison of SARS-CoV-2 neutralizing antibody and specific antibody determination results [J]. Laboratory Medicine, 2023, 38(4): 352-356.
[4]	ZENG Yanfen, WU Quanming, ZHOU Huan, ZHANG Qiuqin, KANG Yanli, LI Yao, CHEN Xijun, HUANG Jiangang, CHEN Falin. Determination limits of a severe acute respiratory syndrome coronavirus 2 nucleic acid determination reagent in 4 determination systems [J]. Laboratory Medicine, 2023, 38(3): 261-266.
[5]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[6]	YANG Danping, WANG Hong, WANG Can, CHEN Wei, YANG Aiping. Diagnostic efficacy and clinical application evaluation of SARS-CoV-2 antigen determination [J]. Laboratory Medicine, 2023, 38(1): 28-31.
[7]	YUE Caidie, LI Junyan, DING Aijun, XIE Li, ZENG Weikun. Research progress of rapid determination methods for SARS-CoV-2 antigen [J]. Laboratory Medicine, 2023, 38(1): 87-93.
[8]	CHEN Qian, SHAN Zhiming, SONG Chao, KANG Fengfeng, JIN Jing, LI Weixing. Status of quality management of new laboratories for nucleic acid determination of SARS-CoV-2 in Zhejiang [J]. Laboratory Medicine, 2022, 37(7): 669-673.
[9]	JU Yinghui, MO Huifang, WU Hui, CHEN Pu, GUO Wei, WANG Beili. Performance comparison of lymphocyte subset determination by 6-color flow cytometry with 2 different reagents [J]. Laboratory Medicine, 2022, 37(3): 270-273.
[10]	XUE Yan, XU Li, DANG Liheng, WANG Chao, CUI Yaqiong, WANG Ping, WANG Ning, ZHANG Xinjie, LIU Yang. Interference of high levels of bilirubin on lymphocyte subset determination in peripheral blood by flow cytometry and its elimination methods [J]. Laboratory Medicine, 2022, 37(12): 1169-1173.
[11]	HE Yaya, CHEN Shanshan, LI Yongsheng, LIU Juan. Expressions of sLAIR-1 and LAIR-1 mRNA in AS patients and their relationship with disease activity [J]. Laboratory Medicine, 2022, 37(10): 915-920.
[12]	GE Yanmei, HAN Jianxiang, JI Wenli, GAO Daqing, TONG Huacheng. Analysis of serum SARS-CoV-2 IgM,IgG and neutralizing antibody levels in an adult population vaccinated with SARS-CoV-2 [J]. Laboratory Medicine, 2022, 37(1): 47-50.
[13]	ZHANG Yunli, WANG Xin, SHAO Ling, QU Bo, ZHAO Hongmei. Comparison of different nucleic acid extraction methods for the detection of SARS-Cov-2 [J]. Laboratory Medicine, 2021, 36(5): 530-534.
[14]	HUANG Fei, ZHANG Chunyan, GUO Wei, PAN Baishen, WANG Beili. Status and problems of SARS-CoV-2 nucleic acid detection [J]. Laboratory Medicine, 2021, 36(5): 554-559.
[15]	CHEN Jianbo, YANG Yong, LI Huiyuan, REN Chanjun, DU Juan, LI Genshi, TAO Ran, CHEN Jingxian, ZHANG Ling, LI Miao. Comparison of 4 commercial kits for detecting SARS-CoV-2 nucleic acid [J]. Laboratory Medicine, 2021, 36(4): 396-399.